ClinicalTrials.gg
WithdrawnNCT07120737Updated Nov 2, 2026

Efficacy and Safety of Spectacle Lenses With H.A.L.T. MAX Technology on High Myopia Control in Children and Adolescents

An interventional study of H.A.L.T. MAX spectacles in Myopia and High Myopia, sponsored by Shanghai Eye Disease Prevention and Treatment Center. Withdrawn at 1 site in China. Open to participants aged 7 Years to 14 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Shanghai Eye Disease Prevention and Treatment Center · Not applicable, Interventional, and Prevention

How we know

Why this study was withdrawn
Major amendment for protocol
Updated Nov 2, 2026Now WithdrawnStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
7 Years to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Myopia by Shanghai Eye Disease Prevention and Treatment Center — 21 open to participants now, 22 under way, none of them phase 3. Myopia · Shanghai Eye Disease Prevention and Treatment Center.

Enrollment
36th of 36
0 · median 141
Started
2026
with 9 others
No phase
32 of 42
18 open now
Registered
29th of 42
by date

Among the 42 studies in Myopia by Shanghai Eye Disease Prevention and Treatment Center, this one is the 36th largest by enrollment of the 36 interventional ones that give a count, is one of 10 that started in 2026, is one of 32 with no phase, and was the 29th registered.

Myopia

1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

21 of the 42 studies in Myopia by Shanghai Eye Disease Prevention and Treatment Center are open now, in 1 country. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

Where they have run

Who these studies take

Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.

This study: 7 Years to 14 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Myopia by Shanghai Eye Disease Prevention and Treatment Center, or all of them as a file.
02

Study summary

Children aged 7-14 years with high myopia were randomly assigned to a control group or an intervention group at a 1:1 ratio. The intervention group wore H.A.L.T. MAX lenses for at least 10 hours per day for 2 years, and the control group wore ordinary single-vision (SV) spectacles for at least 10 hours per day. At the 1-year follow-up examination (6-month visit), control subjects whose equivalent spherical diopter change (SER) was ≥0.75 D were switched to H.A.L.T. MAX lenses until the end of year 2. After entering year 2, all remaining control (SV) subjects will be replaced with H.A.L.T. MAX defofocus frames for at least 10 hours per day until the end of year 2. And continue to wear it for at least 10 hours per day. To evaluate the efficacy, safety and compliance of H.A.L.T. MAX lenses in delaying myopia progression in children with high myopia, and to provide a scientific basis for the formulation and practice of public health programs for delaying myopia progression and the risk of blindness and visual impairment caused by high myopia.

Read the detailed description

In a 2-year randomized controlled study, the intervention group wear H.A.L.T. MAX spectacle lenses for more than 10 hours a day for 2 years. During the first year, the control group wore conventional single-vision (SV) spectacles for at least 10 hours per day. At the 6-month follow-up visit, if the spherical equivalent refraction (SER) change in the control group (SV) participants was ≥0.75 D, they were switched to H.A.L.T. MAX spectacle lenses until the end of the second year. In the second year, all remaining control group (SV) participants were transitioned to H.A.L.T. MAX defocus spectacle lenses and continued wearing them until the study concluded. To evaluate the efficacy, safety and compliance of H.A.L.T. MAX lenses for delaying myopia in children with high myopia, and to provide a scientific basis for the development of prevention strategies for children with high myopia.

03

Conditions studied

  • Myopia
  • High Myopia

Browse trials for

Keywords

  • myopia
  • high myopia
04

Who can participate

Ages eligible
7 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary, willing to follow the protocol, able to read and understand the information form and give free and (for parents/guardian of children subjects) and assent (for subjects aged 7-14 years old);
  • 7-14 years old,regardless of sex;
  • Spherical equivalent refraction (SE) after cyclopegia ≤ -5.00 D and ≥ -9.00D;
  • Anisometropia and Astigmatism ≤2.50D;
  • Best corrected distance visual acuity of at least 0.8 in both eyes;
  • Willing to wear only the spectacles provided by the investigator for all days (>10 hours) during the study without additional interventions;
  • Accept randomization;
  • Able to sign the informed consent form with the accompaniment and understanding of parents or guardians.

Exclusion criteria

Exclusion Criteria:

  • Allergic or intolerant to cycloplegic drugs;
  • Exclude children on high dose atropine (1%) or red light therapy;
  • Any previous history of myopia control treatment in the previous 30 days, like low dose atropine, defocus spectacles, or thokeratology and acupuncture;
  • History or presence of an ocular disease, strabismus or amblyopia or other binocular vision abnormalities, accommodation dysfunction, and cataract.;
  • History of eye surgery;
  • Ocular or systemic diseases that may be associated with myopia, such as Marfan syndrome, retinopathy of newborns, diabetes, etc;
  • Anatomic or skin factors affecting the wearing of spectacles;
  • Other conditions unsuitable for inclusion (patients with excessive expectations for the effect of the defocus spectacle lenses or desires to try other myopia interventions).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    the intervention group

    the intervention group wore H.A.L.T. MAX for at least 10 hours a day for 2 years.

    Device: H.A.L.T. MAX spectacles

  • No intervention
    The control group

    The control group will wear single vision lenses (SV) for at least 10 hours a day. In the first year (at 6-month follow-up), study participants in the control group with a spherical equivalent diopter change (SER) of ≥0.75 D will be switched to H.A.L.T. MAX lenses until the end of year 2. After entering year 2, all remaining control (SV) study participants will be replaced with H.A.L.T. MAX spectacles for at least 10 hours per day until the end of year 2.

Interventions

  • DeviceH.A.L.T. MAX spectacles

    The Essilor® Stellest® 2.0 lens features a 2 times larger signal area, significantly enhancing the effect of slowing down myopia progression

06

What researchers measure

Primary outcomes

  1. the proportion of change in SER of ≤ -0.75 (D)

    the proportion of change in SER of ≤ -0.75 (D) at the end of 1-year in both groups

    Time frame: at the end of 1-year

Secondary outcomes

  1. The proportion of change in AL of ≥ 0.34 mm

    The proportion of change in AL of ≥ 0.34 mm at the end of 1-year in both groups

    Time frame: at the end of 1-year

Other outcomes

  1. Adaptation outcome

    visual quality, assessed by specify questionnaire.

    Time frame: at the end of 1-year

  2. Adverse events incidence

    Number of participants with adverse events (e.g., headache, dizziness) attributed to lens wear.

    Time frame: 1 year

  3. Exploratory outcomes1

    Changes in SER and AL in the SVL switch over group in the second year.

    Time frame: at the end of 2-year

  4. Exploratory outcomes2

    Changes in choroidal thickness from baseline in the intervention and control group by OCT.

    Time frame: at the end of 2-year

07

Study locations

1 site
  • Shanghai Eye Disease Prevention and Treatment Center (SEDPTC)
    Shanghai, Shanghai Municipality 200336, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Oct 2026 to primary completion in Oct 2026, 0 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: start Sep 2025 → Oct 2026, primary completion Mar 2028 → Oct 2026 and completion Dec 2028 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2025
First posted
Aug 13, 2025
StartActual
Oct 30, 2026was Sep 2025
Primary completionActual
Oct 30, 2026was Mar 2028
CompletionActual
Oct 30, 2026was Dec 2028
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Withdrawn Major amendment for protocol
changed Nov 2, 2026
Start date
Sep 1, 2025→Oct 30, 2026 (actual)
Nov 2, 2026
Primary completion
Mar 1, 2028→Oct 30, 2026 (actual)
Nov 2, 2026
Study completion
Dec 1, 2028→Oct 30, 2026 (actual)
Nov 2, 2026
Enrollment
224 (estimated)→0 (actual)
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Not yet recruiting→Withdrawn
    Why stopped Major amendment for protocol
    Start date Sep 1, 2025→Oct 30, 2026 (now actual)
    Primary completion Mar 1, 2028→Oct 30, 2026 (now actual)
    Study completion Dec 1, 2028→Oct 30, 2026 (now actual)
    Enrollment 224 (estimated)→0 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07120737
Lead sponsor
Shanghai Eye Disease Prevention and Treatment Center
Responsible party
Sponsor
First posted
Aug 13, 2025
Start date
Oct 30, 2026
Primary completion
Oct 30, 2026
Completion
Oct 30, 2026
Last update
Nov 2, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion